Huttenlocher Stefan, Seibold Nina D, Gebhard Maximilian P, Noack Frank, Thorns Christoph, Hasselbacher Katrin, Wollenberg Barbara, Schild Steven E, Rades Dirk
Department of Radiation Oncology, University of Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany.
Strahlenther Onkol. 2014 Oct;190(11):1021-7. doi: 10.1007/s00066-014-0694-1. Epub 2014 Jun 14.
To investigate the potential prognostic role of tumor cell podoplanin expression in patients treated with resection followed by irradiation or chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Podoplanin expression (≤10 % versus > 10 %) and 12 other factors were evaluated in 160 patients for their association with locoregional control (LRC), metastases-free (MFS) and overall survival (OS). Other factors were age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, preradiotherapy (pre-RT) hemoglobin level, tumor site, histological grading, T category, N category, American Joint Committee on Cancer (AJCC) stage, human papillomavirus (HPV) status, extent of resection and concurrent chemotherapy.
In multivariate analysis, ECOG performance status 0-1 (risk ratio, RR: 3.01; 95 % confidence interval, CI: 1.42-7.14; p = 0.003), pre-RT hemoglobin levels ≥ 7.45 mmol/l (12 g/dl; RR: 2.03; 95 % CI: 1.04-3.94; p = 0.038), oropharyngeal cancer (RR: 1.25; 95 % CI: 1.01-1.55; p = 0.038) and T category T1-2 (RR: 1.81; 95 % CI: 1.24-2.79; p = 0.002) were significantly associated with improved LRC. T category T1-2 (RR: 1.90; 95 % CI: 1.25-3.06; p = 0.002) and N category N0-2a (RR: 5.22; 95 % CI: 1.96-18.09; p < 0.001) were significantly associated with better MFS. Pre-RT hemoglobin levels ≥ 7.45 mmol/l (RR: 2.44; 95 % CI: 1.27-4.74; p = 0.007), T category T1-2 (RR: 1.97; 95 % CI: 1.36-3.04; p < 0.001) and N category N0-2a (RR: 2.87; 95 % CI: 1.37-6.61; p = 0.005) were significantly associated with improved OS. Podoplanin expression ≤ 10 % showed a trend towards improved OS on both univariate (p = 0.050) and multivariate analysis (RR: 1.86; 95 % CI: 0.96-3.59; p = 0.07).
Treatment outcomes were significantly associated with performance status, pre-RT hemoglobin level, tumor site and tumor stage. Tumor cell expression of podoplanin ≤ 10 % showed a trend towards improved OS when compared to podoplanin expression of > 10 %.
探讨肿瘤细胞血小板源性生长因子表达在接受手术切除后放疗或放化疗的局部晚期头颈部鳞状细胞癌（SCCHN）患者中的潜在预后作用。
评估了160例患者的血小板源性生长因子表达（≤10% 与>10%）以及其他12个因素与局部区域控制（LRC）、无转移生存（MFS）和总生存（OS）的相关性。其他因素包括年龄、性别、东部肿瘤协作组（ECOG）体能状态、放疗前（pre-RT）血红蛋白水平、肿瘤部位、组织学分级、T类别、N类别、美国癌症联合委员会（AJCC）分期、人乳头瘤病毒（HPV）状态、切除范围和同步化疗。
在多因素分析中，ECOG体能状态0 - 1（风险比，RR：3.01；95%置信区间，CI：1.42 - 7.14；p = 0.003）、放疗前血红蛋白水平≥7.45 mmol/l（12 g/dl；RR：2.03；95% CI：1.04 - 3.94；p = 0.038）、口咽癌（RR：1.25；95% CI：1.01 - 1.55；p = 0.038）和T类别T1 - 2（RR：1.81；95% CI：
